Proteus mirabilis urinary tract infection and bacteremia: risk factors, clinical presentation, and outcomes

Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
Chi-Yu ChenChun-Yu Lin

Abstract

Proteus mirabilis is a common pathogen responsible for complicated urinary tract infections (UTIs) that sometimes causes bacteremia. Most cases of P. mirabilis bacteremia originate from a UTI; however, the risk factors for bacteremia and mortality rates from P. mirabilis UTI have not been determined. A retrospective, case-control study was performed between May 2008 and November 2010 to identify the risk factors and markers for P. mirabilis bacteremic UTI. Each subject in the case group (all patients were diagnosed with P. mirabilis bacteremia from a urinary tract source) was matched by age and gender to two subjects in the control group (patients diagnosed with P. mirabilis UTI but with negative blood culture results). Clinical presentation and laboratory data were analyzed to determine the risk factors and markers of P. mirabilis bacteremic UTI. Sixty-seven bacteremic UTIs and 124 nonbacteremic UTIs were included in this study. Community-acquired infection (p=0.017), hydronephrosis (p=0.017), band neutrophils accounting for >10% of the white blood cell count (p=0.001), hyperthermia or hypothermia (p=0.047), and a serum C-reactive protein concentration >100mg/L (p=0.002) were identified as independent risk factors for P. mirab...Continue Reading

References

Dec 1, 1982·The Journal of Infectious Diseases·J W WarrenW C Anthony
Jan 1, 1994·Scandinavian Journal of Infectious Diseases·C Watanakunakorn, S C Perni
Apr 29, 2000·Intensive Care Medicine·C Brun-Buisson
Dec 12, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Annie Wong-BeringerKaren Bush
Apr 16, 2003·Scandinavian Journal of Infectious Diseases·Baek-Nam KimJiso Ryu
Oct 3, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·María VelascoJosé Mensa
Apr 23, 2005·The Journal of Infection·Sari TalAlexander Gurevich
May 19, 2006·International Journal of Antimicrobial Agents·Evangelos J Giamarellos-BourboulisHelen Giamarellou
Oct 13, 2006·The American Journal of the Medical Sciences·Chih-Yang HsuHsiao-Min Chung
Apr 14, 2007·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Y BahagonA M Yinnon
Apr 1, 2008·Journal of Bacteriology·Melanie M PearsonHarry L T Mobley
Feb 2, 2010·The Journal of Infection·Majdi N Al-HasanLarry M Baddour
Jun 29, 2010·Archives of Gerontology and Geriatrics·Bum Sik ChinJune Myung Kim
Nov 3, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C van NieuwkoopJ T van Dissel
Feb 5, 2011·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Ya-Sung YangFeng-Yee Chang

❮ Previous
Next ❯

Citations

Jul 9, 2013·Critical Care Clinics·Lindsay E Nicolle
Sep 13, 2013·Journal of Basic Microbiology·Aysegul Copur CicekCemal Sandalli
Apr 2, 2015·Surgical Infections·Anthony J BottiggiDaniel L Davenport
Nov 12, 2016·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Karin KatoSatoshi Ichiyama
Apr 7, 2017·Intervirology·Ira Aryani WirjonYahya Mat Arip
May 10, 2017·Expert Review of Anti-infective Therapy·Ronald G HallCarlos A Alvarez
Dec 21, 2017·Frontiers in Cellular and Infection Microbiology·Ramanathan SrinivasanArumugam Veera Ravi
Mar 6, 2018·The Journal of Antimicrobial Chemotherapy·Ilyas AlavKhondaker Miraz Rahman
Mar 11, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·William Gustavo LimaMagna Cristina Paiva
Oct 13, 2017·Pakistan Journal of Biological Sciences : PJBS·Ali Al-AsoufiKhaled Khleifat
Sep 15, 2020·Frontiers in Cellular and Infection Microbiology·Reham WasfiLamiaa Ismail Fahmy
May 22, 2018·Open Forum Infectious Diseases·Jesse D SuttonEmily S Spivak
Jun 15, 2019·Archives of Virology·Salwa GomaaHisham Abbas
Oct 13, 2019·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Huan-Cheng LaiHsiu-Yin Chiang
Dec 12, 2020·Biotechnology Reports·Mana OloomiSaeid Bouzari
Feb 10, 2018·EcoSal Plus·Chelsie E ArmbrusterMelanie M Pearson
Jun 6, 2021·International Journal of Pharmaceutics·Li DingZhengrong Cui
Nov 3, 2021·Pathogens and Global Health·Zorada SwartBernard Slippers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.